Throughout the last three months, 4 analysts have evaluated Cara Therapeutics (NASDAQ:CARA), offering a diverse set of opinions from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
4
0
0
0
0
Last 30D
1
0
0
0
0
1M Ago
2
0
0
0
0
2M Ago
0
0
0
0
0
3M Ago
1
0
0
0
0
Analysts have set 12-month price targets for Cara Therapeutics, revealing an average target of $6.25, a high estimate of $10.00, and a low estimate of $5.00. This current average represents a 26.47% decrease from the previous average price target of $8.50.
Breaking Down Analyst Ratings: A Detailed Examination
The perception of Cara Therapeutics by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst
Analyst Firm
Action Taken
Rating
Current Price Target
Prior Price Target
Joseph Stringer
Needham
Maintains
Buy
$5.00
-
Sumant Kulkarni
Canaccord Genuity
Lowers
Buy
$10.00
$11.00
Joseph Stringer
Needham
Maintains
Buy
$5.00
-
Joseph Stringer
Needham
Lowers
Buy
$5.00
$6.00
Key Insights:
Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Cara Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.
Rating: Providing a ...Full story available on Benzinga.com
Related tickers: CARA.
Read Full Article